Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200-250 pCi of "'In-BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl > BLM > "'In-BLM. On the 11th day after the first injection, tumor size (m3) in the "'In-BLM group was 1,2
A new 111in-bleomycin complex for combined radiotherapy and chemotherapy
β Scribed by De-Yan Hou; Hans Hoch; Gerald S. Johnston; K. C. Tsou; Alfred E. Jones; Raymond J. Farkas; Elizabeth E. Miller; Steven M. Larson
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 651 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A new ^111^Inβbleomycin complex (^111^InβBLMC) is here reported. Its radiochemical purity was 99% by thinβlayer chromatography (TLC) (Rf 0.65) and in 5% agarose gel electrophoresis in 0.02 M NaHCO~3~ it migrated toward the anode. Autoradiographs of TLC and gel electrophoresis plates sho
Thirty-one patients with Stage III-IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete r
## Abstract We have found a new ^111^Inβbleomycin complex (BLMC), which has high affinity to tumor, does not bind to transferrin and is stable in vivo. Distribution in animals bearing glioma, hepatoma, or mammary adenocarcinoma at 48 hours showed: the ratios of tumor to blood, brain, heart, lung, l